Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| aTYR PHARMA INCLIFE · Entity 7233 | Chief Scientific Officer | February 06, 2018 | February 08, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
aTYR PHARMA INC
Report date February 06, 2018 · Filed February 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2028-02-06 | Direct | 150,000 |
Reported balance
After 2018-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-06 · Grant · Acquired 150,000 · Balance 150,000 F1: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 6, 2018, such that this option will be fully exercisable on February 6, 2022. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 6, 2018, such that this option will be fully exercisable on February 6, 2022. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2018 Filed Feb 8, 2018 20:47 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001209191-18-008625 · doc4.xml · derivative · entry 1 King David John · CIK 0001684902 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-02-06 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 6, 2018, such that this option will be fully exercisable on February 6, 2022. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 16:09 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001209191-17-009057 · doc4.xml · derivative · entry 1 King David John · CIK 0001684902 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2027-03-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 7, 2017, such that this option will be fully exercisable on February 7, 2021. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| September 21, 2016 Filed Sep 22, 2016 16:53 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 145,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0001209191-16-142490 · doc4.xml · derivative · entry 1 King David John · CIK 0001684902 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2026-09-21 F1 · derivative.exercise_date: 1/4 of the shares subject to this option shall vest and become exercisable on September 21, 2017, and the remainder shall thereafter vest in 36 equal monthly installments, such that this option is fully exercisable on September 21, 2020. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.